STOCK TITAN

Tvardi director granted 6,000 stock options

Tvardi Therapeutics director Sujal Shah received a stock option grant for 6,000 shares of common stock.

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Tvardi Therapeutics director Sujal Shah received a stock option grant for 6,000 shares of common stock. The option has an exercise price of $2.78 per share and expires on June 8, 2036. All 6,000 underlying shares will vest on the earlier of June 9, 2027 or the company’s next annual stockholder meeting, assuming he remains in continuous service.

Positive

  • None.

Negative

  • None.
Insider Shah Sujal
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 6,000 $0.00 $0.00
Holdings After Transaction: Stock Option (right to buy) — 6,000 contracts (Direct)
Footnotes (1)
  1. F1. 100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.
Option grant size 6,000 options Stock Option (right to buy) granted to director
Exercise price $2.78 per share Exercise price of granted stock options
Post-transaction derivative holdings 6,000 options Total options held after grant
Expiration date June 8, 2036 Option term end date
Vesting date trigger June 9, 2027 or next annual meeting 100% vesting on earlier of these dates, with continuous service
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
exercise price financial
"conversion_or_exercise_price: "2.7800""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-06-08T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
continuous service financial
"subject to the Reporting Person's continuous service through such vesting date"
annual meeting of stockholders financial
"the Issuer's next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Tvardi Therapeutics (TVRD) report for Sujal Shah?

Tvardi Therapeutics reported that director Sujal Shah received a grant of stock options for 6,000 shares of common stock. These options were awarded as compensation, not purchased on the open market, and increase his derivative holdings in the company.

What is the exercise price of Sujal Shah’s Tvardi Therapeutics stock options?

The granted stock options have an exercise price of $2.78 per share. This is the fixed price at which he can buy Tvardi Therapeutics common shares if the options vest and he chooses to exercise them before expiration.

When do Sujal Shah’s Tvardi Therapeutics options vest?

All 6,000 shares underlying the options vest 100% on the earlier of June 9, 2027 or Tvardi Therapeutics’ next annual stockholder meeting. Vesting is conditioned on his continuous service with the company through the applicable vesting date.

When do Sujal Shah’s Tvardi Therapeutics stock options expire?

The stock options granted to Sujal Shah expire on June 8, 2036. After this expiration date, any unexercised options become worthless, so he must exercise vested options before then to acquire Tvardi Therapeutics common shares.

How many Tvardi Therapeutics options does Sujal Shah hold after this Form 4 transaction?

Following this transaction, Sujal Shah holds 6,000 stock options directly. These options each relate to one share of Tvardi Therapeutics common stock, giving him the right, but not the obligation, to purchase those shares if they vest and he exercises.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Shah Sujal

(Last)(First)(Middle)
C/O TVARDI THERAPEUTICS, INC.
3 SUGAR CREEK CTR BLVD, STE 525

(Street)
SUGAR LAND TEXAS 77478

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Tvardi Therapeutics, Inc. [ TVRD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$2.7806/09/2026A6,000 (1)06/08/2036Common Stock6,000$06,000D
Explanation of Responses:
1. 100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.
/s/ Dan Conn, Attorney-in-Fact06/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading